Volume–VI, Number–01, January-June, 2011
Business Analysis of Pharmaceutical Firms in Bangladesh: Problems and Prospects MD. ANAMUL HABIB* MD. ZAHEDUL ALAM** Abstract The aim of the study is to present the current scenario of the pharmaceutical industry in Bangladesh. Since inception, there was little consensus on the development of pharmaceutical policies best suited in a developing country such as Bangladesh. Here, the pharmaceutical industry developed rapidly from the 1980s after the introduction of Drug (Control) Ordinance-1982. Adequate infrastructure and use of trained manpower were two essential requisites for implementation of national pharmaceutical policies in Bangladesh. The country was importing significant amount of medicine and also raw materials for the industry from abroad. But the industry has started to export its products in foreign market, especially in the Middle East and Europe with great success. This study tries to identify the major problems of marketing, exporting, production and operations, quality control in the pharmaceutical sector and proposes strategies to overcome these problems, it also identifies the prospects of pharmaceutical industry in Bangladesh.
Keywords: Drug, Problem, Education, Health, Policy, Pharmaceutical, Deficit, Facilities, Executives. 1. INTRODUCTION
The pharmaceutical sector is one of the thrust sectors in Bangladesh. Before Liberation, there was hardly any pharmaceutical enterprise in Bangladesh (then East Pakistan). After several years of liberation, the government could not increase (in relative terms) budgetary allocations for the improvement of health sector. At that time, most of the people had little access to the essential lifesaving medicines. This sector started to improve from 1980s. The pharmaceutical industry has grown in the last two decades at a considerable rate (http://banglapedia). After the promulgation of Drug Control Ordinance-1982, the development of pharmaceuticals industry has accelerated. The skills and MD. Anamul Habib, Senior Lecturer, School of Business Studies, Southeast University, Dhaka. ** Md. Zahedul Alam, Assistant Professor of Marketing, Department of Business Administration, Northern University Bangladesh, Dhaka. *
Journal of Business and Technology (Dhaka)
knowledge of the professionals and innovative ideas of the people involved in this industry are the key factors for these developments. Due to recent development of this sector, the country is exporting medicines to global market including European coutnries and on the top of it, the industry has been supplying about 95 per cent of the domestic demand for medicines. (http://www.pharmadu.net). There are three drug manufacturing units under control of the Government of Bangladesh. Two of them are in Dhaka and another one is in Bogra. The name of these units is Essential Drug Company Ltd. (EDCL), which is operating as a public limited company under the Ministry of Health and Family Welfare. Essential Drug Company Limited produced medicines worth Tk. 964 million in 2000. The production rate of these companies is also increasing day by day. There are separate vaccines and large volume IV fluids production units under the Institute of Public Health (IPH) located in Dhaka. The medicines and other drugs like- vaccine of both Essential Drug Company Limited and Institute of Public Health are mostly used in government hospitals and institutions. In 2000, there were 261 unani, 161 ayurvedic, 76 homeopathic and bio-chemic licensed manufacturing units in Bangladesh. The total worth of their medicines was Tk 1.2 billion in 2000. One of the major positive impacts of Drug (Control) Ordinance-1982 is the rapid development of local manufacturing capability. In recent years, the country has achieved large volume of parental products, by which the country becomesself sufficient; huge volume of these products are also exported to other countries. The development of local manufacturing...
References: Abbott T. A. (1995), “Price regulation in the pharmaceutical industry: Prescription or placebo?” Journal of Health Economics, Volume 14, Issue 5, December 1995, pp. 551-565. Anthony W.P., Perrewe P.L., Kacmar K.M. (2003), “Human Resource Management: A Strategic Approach” Third Edition, The Dryden Press, Harcourt Brace College Publishers, pp. 322-338.
• • • • • •
Journal of Business and Technology (Dhaka)
Braithwaite J. (January, 1993), “Transnational Regulation of the Pharmaceutical Industry” Annals of the American Academy of Political and Social Science, Vol. 525, White-Collar Crime, pp. 12-30. Chowdhury A. I., (2000), “Consumer Behavior” School of Business, Bangladesh Open University, pp. 1- 13. DeCenzo D.A., Robbins S.P. (2005), “Human Resource Management” Seventh Edition, John Wiley & Sons, Inc. pp. 34-45. DiMasi J. A. (2000), “New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms” Drug Information Journal, Vol. 34 pp. 1169–1194. Grace C. (June, 2004), “The Effect of Changing Intellectual Property on Pharmaceutical Industry Prospects in India and China: Considerations for Access to MedicinesIssues paper - Access to medicines, DFID Health Systems Resource Centre, PP. 1-69. Griffin R.W., Pustay M.W. (2001), “International Business: A Managerial Perspective” Third Edition, Pearson Education, Inc. Upper Saddle River, PP. 72-98. http://banglapedia.search.com.bd/HT/P_0154.htm (Retrieved on: December 03, 2009). http://www.pharmadu.net/bps/companyinfo.htm (Retrieved on: December 10, 2009). Humer F.B. (16 March, 2005), “Innovation in the Pharmaceutical Industry —Future Prospects” Talk by Dr Franz B. Humer, Chairman of the Board of Directors and CEO of F. Hoffmann-La Roche Ltd, to the Zürcher Volkswirtschaftliche Gesellschaft Zurich, pp. 1-8. Industrial Policy, 1999. Jayasuriya D. C. (December, 1991), “Pharmaceuticals and Developing Countries: Problems and Prospects” Pharmacy World & Science, Springer Netherlands, Volume 13, Number 6/, 1991, pp. 244-247. Kotler P. and Armstrong G. (2005), “Principles of Marketing” Tenth Edition, PrenticeHall, India Private Company Limited, New Delhi, pp. 1-12. Kremer M. (2002), “Pharmaceuticals and the Developing World” American Economic Association, The Journal of Economic Perspectives, 16, Number 4, 1 November 2002 , pp. 67-90(24). Rugman A.M. & Hodgetts R.M. (2004), “International Business” Third Edition, Pearson Education (Singapore) Pte. Ltd, Indian Branch, pp. 1-5. Shariat Ullah M., Razzak B.M., (2006), “Problems and Prospects of Pharmaceutical Industry in Bangladesh” Journal of Business and Technology, Vol. 01, Issue 01, January- June, 2006, pp. 35-44. Skinner S.J., Ivancevich J.M. (2003), “Business for the 21st century” Richard D. Irwin, Inc. USA, pp. 195- 204. Smith S.E. (May, 2000), “Opening Up to the World: India’s Pharmaceutical Companies Prepare for 2005” Asia/Pacific Research Center, Institute for International Studies, Stanford University, pp. 1-46.
Habib & Alam: Business Analysis of Pharmaceutical Firms in Bangladesh
VanDuzer T. (April, 2003), “TRIPS and the Pharmaceutical Industry in Bangladesh: Towards a National Strategy” CPD Occasional Paper Series, pp. 1-44. Zeller C. (2000), "Rescaling Power Relations between Trade Unions and Corporate Management in a Globalizing Pharmaceutical Industry: the case of the acquisition of Boehringer Mannheim by Hoffman - La Roche" Environment and Planning Act. 32(9) pp. 1545 – 1567.
Please join StudyMode to read the full document